Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service

JAMA. 2014 Feb 26;311(8):793-4. doi: 10.1001/jama.2014.148.

Authors

Nicholas S Downing¹, Joseph S Ross²

Affiliations

¹ Yale University School of Medicine, New Haven, Connecticut.
² Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.

PMID: 24474248
DOI: 10.1001/jama.2014.148

No abstract available

MeSH terms

Community Participation
Consumer Product Safety / legislation & jurisprudence
Genetic Predisposition to Disease*
Genetic Testing / legislation & jurisprudence*
Genetic Testing / standards
Government Regulation*
Humans
Marketing of Health Services / legislation & jurisprudence*
Patient Advocacy
Polymorphism, Single Nucleotide
Risk
United States
United States Food and Drug Administration